A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Inclusion Criteria: * Males or Females age less than or equal to 18 * TEE-defined Grade III or IV atherosclerotic disease of the thoracic aorta documented within the previous 90 days, or established atherosclerotic disease of the lower extremities as demonstrated by: * a history of lower extremity peripheral vascular surgery for obstructive atherosclerotic disease, or * a history of lower extremity peripheral arterial angioplasty for obstructive atherosclerotic disease, or * a history of lower extremity amputation secondary to atherosclerotic disease, or * an ABI \<0.90 within the previous 90 days, or * a history of claudication in patients with documented coronary artery disease (i.e., history of myocardial infarction, coronary revascularization, or coronary angiography demonstrating at least one obstructive coronary lesion with a 50% or greater stenosis). Exclusion Criteria: * Women of childbearing age who do not agree to utilize protocol approved contraceptive methods. * Average pre-dose SBP \< 100 or DBP \< 60. * Patients with any serious disorder including cardiovascular (ventricular arrhythmias, valvular disease or implantable defibrillator), renal, pulmonary, hepatic, gastrointestinal, endocrine/metabolic (excluding patients with controlled diabetes mellitus), hematologic/oncologic (including an active malignancy other than basal cell carcinoma or non-metastatic prostate cancer), neurologic, and psychiatric diseases. * Patients with a history of MI, PTCA, CABG, heart failure, CVA or TIA within the last 30 days.